Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban

Author： Giorgi Mariano A   Cohen Arazi Hernáán   Gonzalez Claudio D   Di Girolamo Guillermo  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.4, 2011-03, pp. : 567-577

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs

By Troncoso Amelia   Diogène Eduard  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 2, 2014-02 ,pp. : 249-250

Springer Publishing Company

Access to resources Recommend Favorite

Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban

By Messori Andrea   Maratea Dario   Fadda Valeria   Trippoli Sabrina  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 4, 2014-04 ,pp. : 505-506

Springer Publishing Company

Access to resources Recommend Favorite

More light at the end of the tunnel – apixaban in atrial fibrillation

By Doggrell Sheila A  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 8, 2012-08 ,pp. : 1235-1239

Informa Healthcare

Access to resources Recommend Favorite

New Advances in Atrial Fibrillation Management: The Role of Apixaban

By  

Current Drug Targets, Vol. 19, Iss. 6, 2018-04 ,pp. : 585-592

Bentham Science Publishers

Access to resources Recommend Favorite

Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation†

By Garnock-Jones Karly P.  

Drugs & Aging, Vol. 28, Iss. 5, 2011-05 ,pp. : 415-419

Adis International

Access to resources Recommend Favorite